H.U. Group Holdings Inc

Chart & Performance

D1W1MN

P/E

—

P/S

0.62

EPS

—

Div Yield, %

4.90%

Shrs. gr., 5y

-0.06%

Rev. gr., 5y

5.49%

Revenues

236.95b

-9.18%

Net income

-7.55b

CFO

16.55b

-49.13%

Dividend

Mar 28, 20250 JPY/sh

Earnings

Feb 07, 2025

Profile

H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosmetic testing services; and testing services through corporate health insurance associations. It also researches, develops, manufactures, and sells in vitro diagnostic devices, which includes the LUMIPULSE, an automatic chemiluminescent enzyme immunoassay system that offers reagents for infectious disease, cancer, and lifestyle disease to medical institutions and testing centers; and ESPRINE, a rapid diagnostics kit series for influenza, hepatitis B, and the novel coronavirus, as well as supplies ingredients for test drugs. In addition, the company provides support services related to hospital administration work, including aid for surgical procedures and endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services; and rents and sells nursing-care equipment and supplies. Further, it offers home-visit nursing care services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.

URL

https://www.hugp.com/

IPO date

Sep 01, 1983

Employees

5,437

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	236,950,000 -9.18%	260,908,000 -4.41%	272,944,000 22.39%
Cost of revenue	184,977,000	180,540,000	168,426,000
Unusual Expense (Income)
NOPBT	51,973,000	80,368,000	104,518,000
NOPBT Margin	21.93%	30.80%	38.29%
Operating Taxes	(66,000)	7,230,000	11,710,000
Tax Rate		9.00%	11.20%
NOPAT	52,039,000	73,138,000	92,808,000
Net income	(7,553,000) -148.18%	15,676,000 -47.04%	29,599,000 69.45%
Dividends	(7,143,000)	(7,139,000)	(8,906,000)
Dividend yield	5.14%	4.71%	5.38%
Proceeds from repurchase of equity	(987,000)	(1,000)	(498,000)
BB yield	0.71%	0.00%	0.30%
Debt
Debt current	13,849,000	7,803,000	7,650,000
Long-term debt	79,941,000	82,825,000	81,027,000
Deferred revenue		(3,838,000)	(2,011,000)
Other long-term liabilities	16,179,000	14,147,000	10,307,000
Net debt	46,634,000	17,237,000	10,569,000
Cash flow
Cash from operating activities	16,551,000	32,535,000	55,229,000
CAPEX	(12,370,000)	(21,686,000)	(35,125,000)
Cash from investing activities	(16,050,000)	(29,583,000)	(30,862,000)
Cash from financing activities	(5,782,000)	(5,757,000)	(21,725,000)
FCF	47,887,000	61,299,000	77,900,000
Balance
Cash	39,947,000	44,412,000	46,711,000
Long term investments	7,209,000	28,979,000	31,397,000
Excess cash	35,308,500	60,345,600	64,460,800
Stockholders' equity	119,760,000	271,741,000	253,364,000
Invested Capital	205,319,500	175,390,400	151,176,200
ROIC	27.34%	44.79%	65.05%
ROCE	21.60%	33.55%	48.02%
EV
Common stock shares outstanding	56,886	56,902	56,985
Price	2,443.00 -8.36%	2,666.00 -8.23%	2,905.00 -21.80%
Market cap	138,972,498 -8.39%	151,700,732 -8.36%	165,541,425 -21.86%
EV	185,606,498	313,569,732	312,170,425
EBITDA	72,843,000	100,062,000	119,144,000
EV/EBITDA	2.55	3.13	2.62
Interest	399,000	369,000	395,000
Interest/NOPBT	0.77%	0.46%	0.38%